In a debate on Monday, Budget Committee Members questioned the European Commission’s Health Director General on vaccine availability and the use of the European Union budget.
In her introductory remarks, Sandra Gallina, Director General for Health and Food Safety in the European Commission, explained what the Commission is doing to obtain enough COVID-19 vaccines to reach its objective of having 70% of the EU’s adult population inoculated by the summer. Contracts had to be negotiated rapidly, she said, with liability and indemnification being of paramount importance. The EU has “gone beyond the 12-million-vaccinations mark”, she underlined, saying that “there is no need to envy the US or Israel”.
The Chairman of the Committee on Budgets Johan Van Overtveldt (ECR, BE) emphasised that Members of the European Parliament (MEPs) “did their duty”, by adopting the Emergency Support Instrument in April and managing to triple the EU4Health and boost the Horizon Europe research programmes in the negotiations on the EU long-term budget for 2021-2027.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze